This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
User:Megan Leaman/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 23: | Line 23: | ||
==Regulation== | ==Regulation== | ||
| - | Regulation of DGAT1 is thought to be performed by the hydrophilic N-terminal domain which regulates activity based on acyl-CoA/CoA levels. The N-terminal domain contains an intrinsically disordered region and a folded segment. The disordered region has an autoinhibitory function and a dimerization interface, and the folded segment was found to have an allosteric site of acyl-CoA/CoA. When acyl-CoA levels increase, the binding of acyl-CoA with this non-catalytic site initiates allosteric activation. Enzyme activation is prevented until limiting acyl-CoA conditions, which allows CoA to act as a noncompetitive feedback inhibitor. For these reasons, it is proposed that the N-terminal domain of DGAT1 acts as a positive and negative regulator. <ref name="Caldo">doi.org/10.1104/pp.17.00934</ref> | + | Regulation of DGAT1 is thought to be performed by the hydrophilic N-terminal domain which regulates activity based on acyl-CoA/CoA levels. The N-terminal domain contains an intrinsically disordered region and a folded segment. The disordered region has an autoinhibitory function and a dimerization interface, and the folded segment was found to have an allosteric site of acyl-CoA/CoA. When acyl-CoA levels increase, the binding of acyl-CoA with this non-catalytic site initiates allosteric activation. Enzyme activation is prevented until limiting acyl-CoA conditions, which allows CoA to act as a noncompetitive feedback inhibitor. For these reasons, it is proposed that the N-terminal domain of DGAT1 acts as a positive and negative regulator. <ref name="Caldo">Caldo, K., Acedo, J. Z., Panigrahi, R., Vederas, J. C., Weselake, R. J., & Lemieux, M. J. (2017). Diacylglycerol Acyltransferase 1 Is Regulated by Its N-Terminal Domain in Response to Allosteric Effectors. Plant physiology, 175(2), 667–680. https://doi.org/10.1104/pp.17.00934</ref> |
==Inhibitors== | ==Inhibitors== | ||
| Line 42: | Line 42: | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
<references/> | <references/> | ||
==Student Contributors== | ==Student Contributors== | ||
Revision as of 14:40, 27 April 2021
Human Diacylglycerol O-Transferase 1
| |||||||||||
References
- ↑ Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, Novak S, Collins C, Welch CB, Lusis AJ, Erickson SK, Farese RV Jr. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13018-23. PMID:9789033
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Sui X, Wang K, Gluchowski NL, Elliott SD, Liao M, Walther TC, Farese RV Jr. Structure and catalytic mechanism of a human triacylglycerol-synthesis enzyme. Nature. 2020 May;581(7808):323-328. doi: 10.1038/s41586-020-2289-6. Epub 2020 May, 13. PMID:32433611 doi:http://dx.doi.org/10.1038/s41586-020-2289-6
- ↑ Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res. 2008 Nov;49(11):2283-301. doi: 10.1194/jlr.R800018-JLR200. Epub 2008, Aug 29. PMID:18757836 doi:http://dx.doi.org/10.1194/jlr.R800018-JLR200
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Wang L, Qian H, Nian Y, Han Y, Ren Z, Zhang H, Hu L, Prasad BVV, Laganowsky A, Yan N, Zhou M. Structure and mechanism of human diacylglycerol O-acyltransferase 1. Nature. 2020 May;581(7808):329-332. doi: 10.1038/s41586-020-2280-2. Epub 2020 May, 13. PMID:32433610 doi:http://dx.doi.org/10.1038/s41586-020-2280-2
- ↑ Caldo, K., Acedo, J. Z., Panigrahi, R., Vederas, J. C., Weselake, R. J., & Lemieux, M. J. (2017). Diacylglycerol Acyltransferase 1 Is Regulated by Its N-Terminal Domain in Response to Allosteric Effectors. Plant physiology, 175(2), 667–680. https://doi.org/10.1104/pp.17.00934
- ↑ Denison, H., Nilsson, C., Löfgren, L., Himmelmann, A., Mårtensson, G., Knutsson, M., Al-Shurbaji, A., Tornqvist, H., & Eriksson, J. W. (2014). Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes, obesity & metabolism, 16(4), 334–343. https://doi.org/10.1111/dom.12221
- ↑ Cao, J., Zhou, Y., Peng, H., Huang, X., Stahler, S., Suri, V., Qadri, A., Gareski, T., Jones, J., Hahm, S., Perreault, M., McKew, J., Shi, M., Xu, X., Tobin, J. F., & Gimeno, R. E. (2011). Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. The Journal of biological chemistry, 286(48), 41838–41851. https://doi.org/10.1074/jbc.M111.245456
- ↑ Haas, J. T., Winter, H. S., Lim, E., Kirby, A., Blumenstiel, B., DeFelice, M., Gabriel, S., Jalas, C., Branski, D., Grueter, C. A., Toporovski, M. S., Walther, T. C., Daly, M. J., & Farese, R. V., Jr (2012). DGAT1 mutation is linked to a congenital diarrheal disorder. The Journal of clinical investigation, 122(12), 4680–4684. https://doi.org/10.1172/JCI64873
- ↑ Gluchowski, N. L., Chitraju, C., Picoraro, J. A., Mejhert, N., Pinto, S., Xin, W., Kamin, D. S., Winter, H. S., Chung, W. K., Walther, T. C., & Farese, R. V., Jr (2017). Identification and characterization of a novel DGAT1 missense mutation associated with congenital diarrhea. Journal of lipid research, 58(6), 1230–1237. https://doi.org/10.1194/jlr.P075119
Student Contributors
- Megan Leaman
- Grace Hall
- Karina Latsko
